Apellis Pharmaceuticals Inc (NASDAQ:APLS) Shorted Shares Increased 21.1% After Market Selling

April 18, 2018 - By Louis Casey

The stock of Apellis Pharmaceuticals Inc (NASDAQ:APLS) registered an increase of 21.1% in short interest. APLS’s total short interest was 1.64 million shares in April as published by FINRA. Its up 21.1% from 1.35 million shares, reported previously. With 170,900 shares average volume, it will take short sellers 10 days to cover their APLS’s short positions. The short interest to Apellis Pharmaceuticals Inc’s float is 6.95%.

The stock decreased 16.60% or $4.98 during the last trading session, reaching $25.02. About 591,298 shares traded or 418.92% up from the average. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 0.00% since April 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $1.26 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. It currently has negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.